Post-discharge use of opioids, psychostimulants, and treatment medications following residential opioid discontinuation with NET Device™ monotherapy

The randomized groups did not differ on outcomes. However, participants who self-administered active NET Device stimulation >24 hours reported significantly fewer post-discharge days of opioid or psychostimulant use than those who self-administered active <24 hours or sham, but these findings need to be replicated.Clinical Trial Registration: ClinicalTrials.gov, identifier NCT04916600.